Altimmune Inc. Common Stock (ALT)

About ALT

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

57

Website

altimmune.com

Fundamentals

1-day range

$2.86$2.97

Market cap

$583.42M

P/E (trailing)

—

P/E (forward)

-4.22

EPS (trailing)

$-0.76

Dividend yield

—

Beta

0.17

Avg. volume

4.14M

Ex-dividend date

January 20, 2017

Dividend pay date

September 14, 2018

Forecasts

9 analyst ratings

Altimmune Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALT

  Altimmune Inc. Common Stock

  $3.11

  ▼ 4.01%
  Market cap $583.42MP/E —
  $2.56$6.44
• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $592.31MP/E 3.53
  $6.13$14.96
• MPLT

  MapLight Therapeutics Inc. Common Stock

  $12.64

  ▲ 0.80%
  Market cap $569.09MP/E —
  $9.1$40.43
• CBIO

  Crescent Biopharma Inc. Common Stock

  $17.74

  ▼ 0.14%
  Market cap $552.33MP/E —
  $8.72$27.41
• ARVN

  Arvinas Inc. Common Stock

  $9.16

  ▼ 0.87%
  Market cap $520.04MP/E 62.96
  $6.97$14.51
• BBOT

  BridgeBio Oncology Therapeutics Inc. Common Stock

  $8.74

  ▼ 4.79%
  Market cap $660.88MP/E —
  $7$14.87
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $676.28MP/E —
  $1.54$18.33

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
  Yahoo · 8/14/2026
• 9 Health Care Stocks Whale Activity In Today’s Session
  Benzinga · 8/14/2026
• ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
  Yahoo · 8/13/2026
• Altimmune: Pemvidutide Performs, But A Long Wait Ahead
  SeekingAlpha · 8/13/2026
• Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...
  Yahoo · 8/12/2026
• Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Altimmune Q2 Earnings Call Highlights
  Yahoo · 8/12/2026
• BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
  Yahoo · 8/12/2026

• Jerome Benedict Durso · August 13, 2026 · Buy

  15.0K @ $2.95
• M. Scot Roberts · July 31, 2026 · Grant

  875 @ $2.41
• Gregory L. Weaver · July 31, 2026 · Grant

  1.8K @ $2.41
• Wayne Pisano · May 1, 2026 · Grant

  48.8K
• Hodges Philip · May 1, 2026 · Grant

  48.8K
• Diane Jorkasky · May 1, 2026 · Grant

  48.8K
• Lawver Teri L · May 1, 2026 · Grant

  48.8K
• Schafer Klaus · May 1, 2026 · Grant

  48.8K
• Catherine A. Sohn · May 1, 2026 · Grant

  48.8K
• John Gill · May 1, 2026 · Grant

  48.8K
• SAYARE MITCHEL · May 1, 2026 · Grant

  48.8K
• John Gill · April 6, 2026 · Buy

  9.2K @ $3.41
• Jerome Benedict Durso · April 1, 2026 · Buy

  15.0K @ $3.14
• Gregory L. Weaver · April 1, 2026 · Buy

  10.0K @ $3.15
• Jerome Benedict Durso · March 6, 2026 · Buy

  20.0K @ $3.54

Institutional Ownership

March 31, 2026

Total shares held

64.90M

Total value held

$198.52M

Institutional holders

167